Here the authors identify distinct mechanisms by which domain-specific p53 mutations activate cancer cell growth via the epidermal growth factor receptor (EGFR). These mechanisms affect sensitivity to EGFR inhibitors, opening avenues for targeted therapy.
- Teresa Lai Fong Ho
- May Yin Lee
- Ashok R. Venkitaraman
